Literature DB >> 10483874

Soluble CD23 in allergic diseases.

B Rogala1, B Rymarczyk.   

Abstract

CD23, a differentiation marker of B cells is identified with the low-affinity receptor for IgE--FcepsilonRII. The CD23 molecule is continuously cleaved by autoproteolysis into soluble fragments called sCD23, considered as a multifunctional cytokine. sCD23 is supposed to play an important role in IgE synthesis. IgE is a hallmark of atopy and its overproduction is a characteristic feature of allergic diseases. The aim of this study was to determine sCD23 (25 kDA) serum levels in patients with inhalant allergy and hymenoptera venom-induced allergy with relevance to IgE system. The trial consisted of 18 patients with pollinosis, 25 with house dust mite allergy and 12 with hymenoptera venom-induced allergy. Eighteen healthy volunteers without signs of atopy served as a control group. Serum levels of sCD23 (25 kDa), total IgE and allergen specific IgE were measured as well. The results were presented as median value, 25-75% range and a total value range. Nonparametric tests (the U Mann-Whitney test, Kruskal and Wallis test and Spearman's correlation rang test) were used. In patients with allergic disorders serum levels of sCD23 were significantly higher than in the control group (p<0.05). No correlation between IgE levels and sCD23 was detected in all the investigated groups. sCD23 does not appear to be a hallmark of allergic diseases, however serum level of that molecule is significantly elevated in patients suffering from allergic disorders. No correlation between sCD23 and IgE has been observed. sCD23 serum level has no relevance to the types of allergic diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10483874

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  3 in total

Review 1.  Soluble IgE receptors--elements of the IgE network.

Authors:  Barbara Platzer; Floortje Ruiter; John van der Mee; Edda Fiebiger
Journal:  Immunol Lett       Date:  2011-09-06       Impact factor: 3.685

Review 2.  Omalizumab and IgE in the Control of Severe Allergic Asthma.

Authors:  Yasuhiro Gon; Shuichiro Maruoka; Kenji Mizumura
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

3.  Oral delivery of a probiotic induced changes at the nasal mucosa of seasonal allergic rhinitis subjects after local allergen challenge: a randomised clinical trial.

Authors:  Kamal Ivory; Andrew M Wilson; Prasanna Sankaran; Marta Westwood; Justin McCarville; Claire Brockwell; Allan Clark; Jack R Dainty; Laurian Zuidmeer-Jongejan; Claudio Nicoletti
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.